2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-175782
    SMU-R39 98%
    SMU-R39 is a TLR7 and TLR8 antagonist with IC50 values of 3.22 μM and 0.24 μM, respectively. SMU-R39 binds to recombinant mTLR7 protein (KD = 2.36 μM) and to recombinant hTLR8 protein (KD = 105 nM). SMU-R39 suppresses downstream NF-κB and MAPK signaling, and reduces secretion/transcription of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) in PBMCs and THP-1 cells. SMU-R39 demonstrates anti-inflammatory efficacy in Imiquimod (IMQ) (HY-B0180)-induced psoriasis mouse model. SMU-R39 can be used for the study of autoimmune diseases such as psoriasis.
    SMU-R39
  • HY-175813
    NPSR1 antagonist-1
    NPSR1 antagonist-1 is a potent and peripherally restricted neuropeptide S receptor 1 (NPSR1) antagonist. NPSR1 antagonist-1 can inhibit IL-6, PTGS2, IL-20, and CXCL8 expression. NPSR1 antagonist-1 can reduce TNF-α cytokine levels. NPSR1 antagonist-1 can be used for the research of inflammation, such as peritonitis.
    NPSR1 antagonist-1
  • HY-175814
    NLRP3-IN-83 98%
    NLRP3-IN-83 is a selective and orally active NLRP3 inflammasome activation inhibitor. NLRP3-IN-83 exhibits good inhibitory IL-1β activity with an IC50 of 1.4 μM by blocking NLRP3, independent of NF-κB signaling. NLRP3-IN-83 only slightly inhibits AIM2 inflammasome pathway, but has no effect on NLRC4 inflammasome. NLRP3-IN-83 prevent cell pyroptosis and exhibits significant anti-inflammatory efficacy in ulcerative colitis model. NLRP3-IN-83 can be used for the study of inflammatory bowel disease (IBD).
    NLRP3-IN-83
  • HY-175832
    PDE4B-IN-5 3029535-85-8
    PDE4B-IN-5 (compound 84) is a PDE4B inhibitor, with an IC50 value <10 nM. PDE4B-IN-5 has anti-inflammatory activity.
    PDE4B-IN-5
  • HY-175833
    NF-κB-IN-20
    NF-κB-IN-20 is an orally active NF-κB inhibitor. NF-κB-IN-20 directly binds to the Keap1 protein, activating the Keap1/Nrf2/HO-1 antioxidant pathway, and simultaneously inhibiting the NF-κB inflammatory pathway, thereby synergistically reducing oxidative stress and inflammatory responses. NF-κB-IN-20 M11 inhibits the expression of IL-6, IL-1β, and TNF-α, significantly reduces the level of ROS, and restores the mitochondrial membrane potential. NF-κB-IN-20 can be used for the study of acute lung injury (ALI).
    NF-κB-IN-20
  • HY-175864
    EGFR-IN-173 98%
    EGFR-IN-173 is an orally active, pan-mutant EGFR tyrosine kinase inhibitor that targets EGFR 19del, L858R/T790M and C797S triple-mutations, potently inhibiting EGFR19del/T790M/C797S with an IC50 of 1.19 nM while showing over 100-fold selectivity for mutant over wild-type EGFR (IC50 = 19.362 μM against WT). EGFR-IN-173 significantly inhibits cell migration, induces apoptosis in non-small cell lung cancer (NSCLC) cells. EGFR-IN-173 inhibits EGFR phosphorylation and suppresses the downstream pathways (MAPK/ERK, AKT, STAT3). EGFR-IN-173 exhibits antitumor efficacy in NSCLC and Ba/F3 xenograft models. EGFR-IN-173 can be used for NSCLC research.
    EGFR-IN-173
  • HY-175876
    ADAM17-IN-1 1802395-34-1
    ADAM17-IN-1 is a selective inhibitor of ADAM17. ADAM17-IN-1 inhibits ADAM17 activity to reduce metabolic activity of dendritic cells (DCs), impair DC antigen-presenting function, suppress allergen-specific Th2 cell polarization, and reduce Th2 cytokine (IL-4, IL-5, IL-13) secretion. ADAM17-IN-1 demonstrates protective efficacy against house dust mite (HDM)-induced type 2/eosinophilic airway inflammation in mice. ADAM17-IN-1 can be used for the study of type 2-high allergic asthma.
    ADAM17-IN-1
  • HY-17589S
    Chloroquine-d5 diphosphate 1854126-42-3 98%
    Chloroquine-d5 (diphosphate) is the deuterium labeled Chloroquine (phosphate). Chloroquine phosphate is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine phosphate is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine phosphate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM).
    Chloroquine-d5 diphosphate
  • HY-175984
    S1P1 agonist 7 98%
    S1P1 agonist 7 is a potent, orally active, and β-arrestin-biased S1P1 agonist (EC50(G‑protein) = 12.7 nM and EC50(β‑arrestin) = 3.23 nM). S1P1 agonist 7 demonstrates potent immunomodulatory activity and a favorable safety profile. S1P1 agonist 7 exhibits excellent metabolic stability, minimal to moderate CYP inhibition, and S1P3-sparing selectivity. S1P1 agonist 7 shows pharmacokinetics, effectively reduces circulating lymphocytes, and significantly alleviates disease severity in experimental autoimmune encephalomyelitis (EAE) mouse models under both prophylactic and therapeutic regimens. S1P1 agonist 7 can be used for multiple sclerosis (MS) research.
    S1P1 agonist 7
  • HY-175985
    MPO-IN-9 3030264-54-8
    MPO-IN-9 is a selective inhibitor of myeloperoxidase (MPO), with an IC50 value of 3.9 nM. MPO-IN-9 inhibits MPO-mediated ROS production and protects NO-dependent vascular function by blocking MPO's chlorination and peroxidation cycles. MPO-IN-9 can be used for the study of diseases such as chronic kidney disease (CKD), non-alcoholic steatohepatitis (NASH).
    MPO-IN-9
  • HY-175986
    IP receptor agonist 1 3029113-61-6
    IP receptor agonist 1 (compound 6c-14S) is an orally active IP receptor agonist, with an IC50 of 0.15 μM for inhibiting platelet aggregation induced by ADP (HY-W010918,300 μM) in rabbit platelet-rich plasma. IP receptor agonist 1 can be used for study of Pulmonary arterial hypertension.
    IP receptor agonist 1
  • HY-176000
    Sulphostin 98%
    Sulphostin is a covalent inhibitor of dipeptidyl peptidase 4 (DPP4), dipeptidyl peptidase 9 (DPP9), and dipeptidyl peptidase 8 (DPP8) with IC50 values of 79, 1392, 6930 nM, respectively. Sulphostin causes phosphosulfamate modification, irreversibly inhibits the enzyme activity. Sulphostin can be used for inflammation and cancer study.
    Sulphostin
  • HY-176001
    DPP8/9-IN-1 98%
    DPP8/9-IN-1 (Compound 16) is a selective covalent inhibitor of dipeptidyl peptidases 8 and 9 (DPP8/9) with IC50 values of 14 and 298 nM, respectively. DPP8/9-IN-1 binds irreversibly to the active site serine (S730 in DPP9) via a phosphonate warhead and blocks substrate binding to inhibit DPP8/9-mediated protein processing. DPP8/9-IN-1 is promising for research of cancers and inflammatory diseases.
    DPP8/9-IN-1
  • HY-176028
    N-Stearoyl-DPPE ammonium 98%
    N-Stearoyl-DPPE ammonium is a type of N-acylphosphatidylethanolamine (NAPE). N-Stearoyl-DPPE ammonium is an important intermediate in the endocannabinoid biosynthesis pathway.
    N-Stearoyl-DPPE ammonium
  • HY-176039
    TUG-2181 2653994-24-0 98%
    TUG-2181 is an antagonist of GPR84 with an IC50 value of 34 nM. TUG-2181 inhibits GPR84 agonists-induced reactive species oxygen (ROS) production and IL-8 release in human neutrophils. TUG-2181 can be used for inflammation and fibrosis study.
    TUG-2181
  • HY-176057
    S118 2677041-36-8 98%
    S118 is an orally active sphingosine-1-phosphate receptor 2 (S1P2 receptor) inhibitor. S118 prevents the binding of the S1P2 receptor to dapper1 (Dpr1), reduces the accumulation of β-catenin and blocks the nuclear translocation of the S1P2 receptor, thereby inhibiting inflammation, fibrosis, and epithelial-mesenchymal transition (EMT) and exerting anti-idiopathic pulmonary fibrosis (IPF) activity. S118 is promising for research of idiopathic pulmonary fibrosis.
    S118
  • HY-176126
    STING agonist-42 2942231-48-1 98%
    STING agonist-42 (compound 8a) is a potent STING agonist. STING agonist-42 activates STING in THP1 and RAW 264.7 cells with EC50s of 0.06 and 14.15 μM, respectively.
    STING agonist-42
  • HY-176131
    AMX5160 2639293-95-9 98%
    AMX5160 (36) is an orally active BTK inhibitor, with an IC50 of 0.98 nM against mutant BTKC481S. AMX5160 (36) can be used in the research for leukemia, lymphoma, multiple sclerosis, and other autoimmune diseases.
    AMX5160
  • HY-176133
    ROCK-IN-12 98%
    ROCK-IN-12 (compound R3) is a selective ROCK inhibitor. ROCK-IN-12 can be used in the study of glaucoma.
    ROCK-IN-12
  • HY-176139
    URAT1 inhibitor 13 2816864-54-5 98%
    URAT1 inhibitor 13 (compound 22k) is a potent URAT1 inhibitor. URAT1 inhibitor 13 can be used in the study of gout .
    URAT1 inhibitor 13
Cat. No. Product Name / Synonyms Application Reactivity